Biotechnology and digital technology developing innovative second and third generation novel compounds to treat mental health and addiction Mydecine Innovations Group. (NEO: MYCO) (OTCMKTS: MYCOF) announced that its exclusive dealer license has been included by Health Canada to operate as a supplier for the Special Access Program (SAP) in Canada.
The Special Access Program allows healthcare professionals to request specific drugs for approved patients who have not responded to other available treatment options or those with life threatening conditions and conventional treatments have failed.
The license identifies Mydecine as an exclusive supplier of psilocybin and MDMA in Canada. The licensed dealer facility includes a unique research and development infrastructure as well as a manufacturing facility in Edmonton, Canada.
The psilocybin and MDMA produced from the facility must meet the Current Good Manufacturing Practices (cGMP) through Health Canada’s Special Access Program.
“While we will continue to advance the research of psychedelic-assisted psychotherapy through our clinical trials and drug development process, we understand there are patients in need of treatments today. Through our dealer’s license, we can offer psilocybin and MDMA to practitioners and clinics in Canada who want to offer these treatment options for patients in need,” said the CMO of Mydecine, Dr. Rakesh Jetly.
